Eikon Therapeutics
Market cap $279M 54.2M shares (10-Q, Nov 2, 2026) × $5.15 close Nov 17, 2026
Most recent annual filing: 2026-03-30
- EIK1004 readout2H 2026EIK1004 readout, 2H 2026, notable
- TeLuRide-008 interim2H 2027TeLuRide-008 interim, 2H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (13 active programs)
IMP1734
IMP17134 · EIK1003IMP1707
IMP17307 · EIK1004EIK1004
EIK1005
- Undisclosed indication
EIK1006
Technology platforms
SMT
Single molecule tracking platform integrating custom-engineered super-resolution microscopy, bespoke automation, advanced data science ML/AI tools, and petabyte-scale data processing. Used to identify and validate novel targets, elucidate mechanisms of action, and accelerate drug candidate identification. Focus areas: oncology and neurologic disease.
single molecule tracking
Proprietary single molecule tracking system used to enable drug discovery and development of internally derived novel oncology therapies; EIK1005 emerged through application of this advanced imaging discovery platform.
Capital (as filed)
- Cash
- $98.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $363M Sep 30, 2026
- Operating cash flow
- −$69.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $462M cash, runway Q1 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (6)
- 2026-11-13 UPDATE: Eikon Therapeutics (EIKN) - The Trigger Slips, the Runway Stretches 🔒 Paid
- 2026-10-27 UPDATE: Eikon Therapeutics (EIKN) - The Durability Test Splits Down the Middle ★ Distilled Pro
- 2026-10-24 UPDATE: Eikon Therapeutics (EIKN) - The Undercard Fight 🔒 Paid
- 2026-08-14 UPDATE: Eikon Therapeutics (EIKN) - The Dispute Quietly Died, the Burn Did Not 🔒 Paid
- 2026-08-12 UPDATE: Eikon Therapeutics (EIKN) - The DMC Picked the Low Dose 🔒 Paid
- 2026-08-05 Eikon Therapeutics (EIKN) — Scientific Deep Dive for EIK1001, EIK1003, and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (6 calls)
Every verdict Biotech Distilled has published on Eikon Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-08-05 Watch Eikon Therapeutics (EIKN) — Scientific Deep Dive for EIK1001, EIK1003, and Pipeline Products Un-patentable lead molecule, single-arm confidence intervals that swallow the SOC benchmark, and an unresolved licensor payment dispute keep the stock on the sidelines until the randomized TeLuRide-006 melanoma interim reads out.
- 2026-08-12 Watch UPDATE: Eikon Therapeutics (EIKN) - The DMC Picked the Low Dose DMC dose selection removes catastrophic-interim risk but discloses zero efficacy data; the named trigger — randomized melanoma efficacy interim — has not fired.
- 2026-08-14 Watch UPDATE: Eikon Therapeutics (EIKN) - The Dispute Quietly Died, the Burn Did Not Seven and Eight licensor dispute resolved (one bear pillar gone), but burn accelerated 77% YoY and no efficacy data moved; named trigger still not fired.
- 2026-10-24 Watch UPDATE: Eikon Therapeutics (EIKN) - The Undercard Fight ESMO day-one data confirms PARP1 blood-sparing for EIK1004 but shows no EIK1001 efficacy; named trigger (randomized melanoma interim) still undated and unfired.
- 2026-10-27 Watch UPDATE: Eikon Therapeutics (EIKN) - The Durability Test Splits Down the Middle Non-squamous DOR resolved below KEYNOTE-189 benchmark and first randomized NSCLC read slipped to 2H 2027; NSCLC leg weakened and a dilutive raise before randomized proof now more likely, but named trigger unchanged.
- 2026-11-13 Watch UPDATE: Eikon Therapeutics (EIKN) - The Trigger Slips, the Runway Stretches Melanoma interim slipped to 1H 2027 and reframed as a futility test, but extended runway now reaches past the readout, reducing forced-raise risk; trigger reset but still unfired.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (6 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We expect to present updated data from TeLuRide-005 at the 2026 European Society of Medical Oncology, or ESMO, Congress in October 2026.”
matched to EIK1001 · interim data -
“We plan to present updated data from Cohort 1A at the ESMO Congress 2026 in October 2026.”
matched to EIK1003 · readout other -
“We plan to present initial clinical data from this trial at the ESMO Congress 2026 in October 2026.”
matched to EIK1005 · readout other
-
-
-
“We expect to present updated data from TeLuRide-005 at the 2026 European Society of Medical Oncology, or ESMO, Congress in October 2026.”
matched to EIK1001 · interim data -
“We plan to present updated data from Cohort 1A at the ESMO Congress 2026 in October 2026.”
matched to EIK1003 · readout other -
“We plan to present initial clinical data from this trial at the ESMO Congress 2026 in October 2026.”
matched to EIK1005 · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (27)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 10, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseEikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
- Nov 12, 2026ReleaseEikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateEikon's Q3 10-Q extends runway guidance to Q1 2028 (up from "into 2H 2027"), narrows THE BIG ONE melanoma interim to 1H 2027, and shows $461.7M cash against a burn rate that has stabilized — but the stock dropped 9.4% anyway, and the dilution gap math still ends at zero cash before the confirmatory NSCLC trial completes.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseEikon Therapeutics to Participate in Multiple Investor Conferences in November
- Oct 26, 2026ReleaseEikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress→ BD updateSummary on the 8-K
- Oct 26, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateToday's full TeLuRide-005 NSCLC readout at ESMO delivers what I called a genuine two-sided catalyst: the squamous cohort posts a respectable 12.9-month median DOR, but non-squamous durability resolves below KEYNOTE-189's benchmark at 11.2 months — and the stock is down 23.7% as the market renders its verdict.BD extracted 1 program update from this document → EIKN pipeline
- Oct 23, 2026ReleaseEikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress→ BD updateSummary on the 8-KBD extracted 1 program update from this document → EIKN pipeline
- Oct 23, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateEikon's ESMO data landed today — EIK1005 posted its first patient efficacy signal (one PR in a MSI-H/dMMR patient on combo, six stable diseases on monotherapy), EIK1004 showed a strikingly clean heme profile (Grade ≥3 anemia/neutropenia each at just 1.5%), and the stock still dropped ~12% during the session, telling you exactly what the market thought of the pipeline read versus the still-absent TeLuRide-006 melanoma interim.BD extracted 2 program updates from this document → EIKN pipeline
- Oct 18, 2026ReleaseEikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology CongressBD extracted 5 program updates from this document → EIKN pipeline
- Oct 15, 2026ReleaseEikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate CancerBD extracted 1 program update from this document → EIKN pipeline
- Sep 3, 2026ReleaseEikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
- Aug 26, 2026ReleaseEikon Therapeutics to Participate in Investor Conferences in September 2026
- Aug 18, 2026ReleaseEikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
- Aug 14, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Aug 13, 2026ReleaseEikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 13, 202610-QQuarterly report
- Aug 11, 2026ReleaseEikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
- Aug 10, 2026ReleaseEikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
- Aug 3, 20268-KCurrent report: officer / director change
- Jun 10, 20268-KCurrent report: officer / director change
- Jun 1, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- May 11, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- May 11, 202610-QQuarterly report
- Mar 30, 20268-KCurrent report: results of operations · EX-99.1
- Mar 30, 202610-KAnnual report
7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Oct 7, 2026SCHEDULE 13G/A13G amendment
- Oct 2, 2026SCHEDULE 13G/A13G amendment
- Aug 6, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 13, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 6, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 29, 2026SCHEDULE 13GPassive >5% holder (13G)